BCRX

BioCryst Pharmaceuticals Inc. Common Stock (BCRX)

Stock · NASDAQ · Health Care

$9.82as of 8/28/2026

Active signals

No technical signal is currently active for this symbol.

Support level
$8.97
Industry
Biotechnology: Biological Products (No Diagnostic Substances)

How BioCryst Pharmaceuticals Inc. Common Stock Makes Money

Where the revenue actually goes — FY2025 annual results

market-wall.comTotalRevenue$874.84MNet Income$263.86M (30%)SG&A$348.65M (40%)R&D$166.13M (19%)Other$73.60M (8%)Cost of Revenue$19.07M (2%)Tax$3.53M (0%)BCRX

Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub

BioCryst Pharmaceuticals Inc. Common Stock Competitors

Chosen by industry and closest market cap.

  • BCRX
    BioCryst Pharmaceuticals Inc. Common Stock
    $9.82
    ▼ 0.51%
    Market cap $2.24BP/E
  • COAG
    Hemab Therapeutics Holdings Inc. Common Stock
    $44.77
    ▼ 9.55%
    Market cap $2.10BP/E
    $23$55.42
  • KOD
    Kodiak Sciences Inc Common Stock
    $37.77
    ▼ 3.45%
    Market cap $2.49BP/E
    $8.29$47.84
  • MESO
    Mesoblast Limited American Depositary Shares
    $17.42
    ▼ 4.18%
    Market cap $1.87BP/E
    $1.88$3.31
  • BEAM
    Beam Therapeutics Inc. Common Stock
    $29.31
    ▼ 3.84%
    Market cap $2.67BP/E
    $16.02$38.26
  • RXRX
    Recursion Pharmaceuticals Inc. Class A Common Stock
    $3.33
    ▼ 3.20%
    Market cap $1.69BP/E
    $2.77$7.18
  • GLUE
    Monte Rosa Therapeutics Inc. Common Stock
    $13.37
    ▼ 6.63%
    Market cap $1.30BP/E
    $4.6$25.77

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held
232.86M
Total value held
$2.18B
Institutional holders
291
Top holders this quarter
  • Unknown22.65M
  • Unknown15.83M
  • Unknown15.04M
  • Unknown12.21M
  • Unknown11.14M
  • Unknown11.02M
  • Unknown8.91M
  • Unknown7.43M
  • Unknown7.03M
  • Unknown6.39M

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.